Health Conversation

Welcome to Health Conversation. Today we're asking Claire Skentelbery, Director General of EuropaBio, 'What is the waiver impact on innovation and pandemic preparedness?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

Welcome to Health Conversation. Today we're asking Koen Berden, Executive Director for International Affairs at EFPIA, 'Why is a therapeutics waiver extension different to the vaccine waiver?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

Welcome to Health Conversation. Today we're asking Jesús Rueda Rodríguez, Strategies, Special Projects & International Affairs Director General at MedTech Europe, 'What would a TRIPS waiver extension mean for diagnostics?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

Welcome to Health Conversation. Today we're asking Peter Guenter, CEO of Healthcare at Merck, 'What would be the impact of a TRIPS waiver extension?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

Welcome to Health Conversation. Today we're asking Nathalie Moll, Director General at EFPIA, 'How can we support medical innovation in Europe?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

Welcome to 19 Conversations. Today we're asking Sara Cerdas, MEP and Mariano Votta, Director, Active Citizenship Network "How can the EU be better prepared for cross-border health threats?". Listen to hear their discussion on the challenge and how we're preparing for the future.